目的 研究南京地区34家医院2013-2015年口服抗消化溃疡药物的使用情况及发展趋势。方法 对2013-2015年南京地区34家医院口服抗消化溃疡药物的用药金额、用药频度（DDDs）、日均费用（DDC）及药品排序比（B/A）等进行统计分析。结果 口服抗消化溃疡药品的用药金额和DDDs逐年增长，质子泵抑制剂逐年增长，胃黏膜保护药增长迅速，抗酸药增长缓慢。雷贝拉唑3年的用药金额均居首位，DDDs排名前2位的是奥美拉唑和兰索拉唑。质子泵抑制剂中，DDC最高的是艾司奥美拉唑，其次是雷贝拉唑钠。将近一半药品的B/A基本接近于1，表明大多数药物同步性较好。结论 质子泵抑制剂是治疗消化性溃疡的首选药物，胃黏膜保护药发展迅速，前景广阔。

Objective To evaluate the utilization and tendency of oral antiseptic ulcer drugs in 34 hospitals from Nanjing area during 2013-2015. Methods Consumption sum, defined daily doses (DDDs), defined daily cost (DDC) and drug sequence ratio (B/A) in 34 hospitals from Nanjing area during 2013-2015were analyzed statistically. Results Consumption sum and DDDs of oral antiseptic ulcer drugs were increased year by year. Consumption sum and DDDs of proton pump inhibitor were increased year by year. Gastric mucosal protective drugs showed a rapid upward trend. While consumption sum and DDDs of antacids showed a slow growth. Consumption sum of rabeprazole ranked first for three years, and the top two were omeprazole and lansoprazole in respect of DDDs. In proton pump inhibitor, DDC of esomeprazole was the highest, and then was rabeprazole sodium. B/A of almost half of the drugs closed to 1.00, indicating that the synchronism was better. Conclusion Proton pump inhibitors are used as the first choice for peptic ulcer. Gastric mucosal protective drugs grow quickly and there exists broad prospects.

江苏高校优势学科建设工程资助项目